Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH48505D
  • |
  • Pages: 258
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 12

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16

Merck KGaA, Medical Devices Deals, 2011 to YTD 2017 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19

Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 29

Asset Purchase 29

Merck KgaA Acquires SevenSeas Original Brand 29

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 29

Venture Financing 30

SerImmune Raises USD8 Million in Venture Financing 30

TocopheRx Raises USD3.3 Million In Seed Financing 31

VAXIMM Secures USD8 Million In Venture Financing 32

Private Equity 33

Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 33

Partnerships 34

Cancer Research Technology Enters into Agreement with Merck 34

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 34

SerImmune Enters into R&D Agreement with Merck 35

Human Longevity Enters into Agreement with Merck 36

F-star Biotech Enters into Partnership with Merck 37

EpiThany Enters into Agreement with Merck and Pfizer 38

VAXIMM Enters into Agreement with Merck and Pfizer 39

Avillion Enters into Co-Development Agreement with Merck 39

Exosome Diagnostics Enters into Agreement with Merck 40

Merck Enters into Agreement with Palantir Technologies 41

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 42

EMD Serono Partners with MD Anderson 43

Evotec Partners with Merck 43

BioMed X Enters into Agreement with Merck 44

Debiopharm Partners with Merck and Pfizer 45

Transgene Enters into Agreement with Merck and Pfizer 46

Vaccinex Enters into Agreement with Merck 47

PCAS Enters into Distribution Agreement with MilliporeSigma 47

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 48

Selvita Enters into Agreement with Merck 49

Merck Enters into Agreement with University of Buea 50

Merck, Pfizer and Verastem Enter into Agreement 50

Merck Enters into Research Agreement with European Molecular Biology Labs 51

Merck, Pfizer and Syndax Pharma Enter into Agreement 52

Selvita Enters into Development and Commercialization Agreement with Merck 53

Biothera Pharma Expands Agreement with Merck 54

Sigma-Aldrich Enters into Agreement with Sanger Institute 54

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 55

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 56

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 56

Aeterna Zentaris Enters into Agreement with EMD Serono 57

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 58

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 59

Merck Serono Enters into Co-Development Agreement with MMV 60

Sigma-Aldrich Enters into Distribution Agreement with Roche 60

Merck Enters into Development Agreement with Precision Biologics 61

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 62

Pfizer Enters into Co-Development Agreement with Merck 62

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 64

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 65

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 65

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 66

Lupin Enters into Co-Development Agreement with Merck Serono 67

Merck Serono Extends R&D Agreement with San Raffaele 68

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 68

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 69

Bionovis Enters into Agreement with Merck 70

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 71

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 72

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 73

Biopharm Enters Into Research Agreement With Merck Serono 73

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 74

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 75

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 76

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 77

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 78

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 79

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 80

Isu Abxis Enters into Co-Development Agreement with Merck 81

Luminex Extends Distribution Agreement With EMD Millipore 82

Alchemia Enters Into Collaboration Agreement with Merck Serono 83

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 83

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 84

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 85

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 85

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 86

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 87

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 88

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 89

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 89

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 90

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 91

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 92

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 93

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 94

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 95

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 95

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 96

Mapi Pharma Amends Co-Development Agreement with Merck 98

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 98

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 99

IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 100

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 101

BASF Enters Into Distribution Agreement With Sigma-Aldrich 102

Lead Discovery Center Enters Into Agreement With Merck Serono 103

Licensing Agreements 104

Selexis Enters into Licensing Agreement with Merck KGaA 104

Merck Enters into Licensing Agreement with Domain Therapeutics 104

Merck Enters into Licensing Agreement with Vertex Pharma 105

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 106

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 107

Merck Enters into Licensing Agreement with Weizmann Institute of Science 108

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 109

EMD Millipore Enters into Licensing Agreement with Singulex 109

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 110

Intrexon Enters into Licensing Agreement with Merck Serono 111

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 112

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 113

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 114

MorphoSys Enters into Licensing Agreement with Merck Serono 115

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 116

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 117

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 118

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 118

ObsEva Enters Into Licensing Agreement With Merck Serono 119

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 120

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 121

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 123

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 123

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 124

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 125

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 126

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 127

Materia Extends Licensing Agreement With Sigma Aldrich 128

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 129

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 129

Ligand Pharma Enters Into Licencing Agreement With Merck 130

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 131

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 132

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 133

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 134

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 135

WntResearch Enters into Licensing Agreement with EMD Millipore 136

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 137

Sigma Life Science Enters Into Licensing Agreement With King's College London 138

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 138

Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 140

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 141

Equity Offering 142

iOnctura Spin Out from Merck and Cancer Research Technology 142

Debt Offering 143

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 143

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 143

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 144

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 144

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 145

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 146

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 146

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 147

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 148

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 149

Asset Transactions 150

Fresenius to Acquire Biosimilars Business from Merck for USD718.4 Million 150

Zydus Healthcare Acquires Six Brands from Merck 151

Martin Dow Acquires Merck Operations in Pakistan 152

Merck May Sell Biosimilars Business 152

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 153

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 154

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 155

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 156

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 157

Acquisition 158

Merck Sells Bangalore Genei for USD1.5 Million 158

Merck Acquires Sigma-Aldrich for USD17 Billion 158

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 160

Merck And BASF Acquire Majority Stake In Innovation Lab 161

Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For USD39 Million 162

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 164

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 164

Proxy Labs Acquires MicroSafe Laboratories From Millipore 165

Sigma-Aldrich Completes Acquisition Of BioReliance For USD350 Million 166

Sigma-Aldrich Acquires Vetec Quimica Fina 168

Sigma-Aldrich Acquires Resource Technology 168

Teva Pharma Industries Acquires THERAMEX From Merck Serono 169

Merck KGaA - Key Competitors 171

Key Employees 172

Locations And Subsidiaries 173

Head Office 173

Other Locations & Subsidiaries 173

Recent Developments 184

Strategy And Business Planning 184

Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 184

Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 185

May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 186

May 12, 2017: Merck Opens First Joint Bioprocess Scale-up Lab with Stelis Biopharma in India 187

Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 188

Jan 10, 2017: Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe 189

Oct 13, 2016: Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap 190

Jun 17, 2016: Merck Family Foundation Established 192

Jun 09, 2016: Consumer Health To Play A Pivotal Role In Merck's Africa Growth Strategy 193

Financial Announcements 194

May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 194

Aug 04, 2016: Merck Lifts Forecast Following Good Second Quarter 196

Jul 29, 2016: Merck Announces Second-Quarter 2016 Financial Results 198

Mar 08, 2016: Merck Finishes Record Year 2015 Stronger 201

Corporate Communications 203

Oct 18, 2016: Apitope regains global rights to ATX-MS-1467 compound 203

Jun 01, 2016: Merck's Belen Garijo Receives Prestigious Career Award 204

Apr 13, 2016: Stand Up To Cancer Launches Catalyst, a New Research Program Supported by Industry 205

Mar 29, 2016: MilliporeSigma's CRISPR Epigenetic Activator Named to The Scientist's Top 10 Innovation List 206

Feb 22, 2016: Merck puts spotlight on women's health and well-being 207

Legal and Regulatory 208

Apr 14, 2016: Merck Responds to Legal Claims in the U.S. 208

Jan 15, 2016: Merck Announces Favorable English Court Ruling on Name Use 209

Government and Public Interest 210

Jul 06, 2017: Merck Biopharma Innovation Cup 2017 210

Jul 05, 2017: Merck Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 211

Jul 05, 2017: Merck KGaA, Darmstadt, Germany Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 212

Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 213

Dec 15, 2016: GeneQuine wins Merck's 2016 European Emerging Biotech Grant Program 214

Oct 10, 2016: Merck Announces Recipients of Third Annual 1 Million Grant for Oncology Innovation' Award 215

Sep 15, 2016: Merck Announces 2016 Recipients of 1 Million Grant for Multiple Sclerosis Innovation 216

Sep 12, 2016: Merck Announces Recipients of the Grant for Growth Innovation 2016 217

Jul 06, 2016: EMD Serono Commits 1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17 218

Jul 06, 2016: Merck Commits 1.5 million to the Grant for Fertility Innovation for 2016/17 219

Product News 220

Oct 04, 2016: Merck Launches Two Innovative Technologies to Support Couples on Their Fertility Treatment Journey 220

Sep 12, 2016: Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets at the 2016 ECTRIMS Congress 221

Sep 08, 2016: Merck Launches New Gene Editing Technology to Engineer Virus Resistant CHO Cell Lines 222

Jun 23, 2017: Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis 223

Jun 08, 2017: BioMed X and Merck launch two new crowdsourcing projects in the fields of cancer research and biologics manufacturing 224

May 22, 2017: Novel Nanobody To Start Clinical Development In Osteoarthritis Ablynx To Receive 15 Million Milestone Payment 225

Apr 28, 2017: Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression 226

Apr 27, 2016: New Merck Products Bring Ease of Use to Single-Use 227

Apr 21, 2017: Merck to Present Data on Cladribine at AAN 2017 228

Apr 03, 2017: Merck Introduces Next-Generation High-Sensitivity Protein Detection Platform 230

Mar 06, 2017: Merck Advances Lab Water Purification Technology with Milli-Q(R) IQ 7000 System 231

Jan 20, 2016: Merck launches Vivera in Latin America 232

Product Approvals 233

Jul 18, 2016: Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets 233

Clinical Trials 234

Jun 26, 2017: Data Provide Additional Insight into the Mode of Action of MAVENCLAD (Cladribine Tablets) in Patients with Relapsing MS 234

Feb 09, 2017: Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with Multiple Sclerosis 235

May 25, 2016: Merck to Present Data on Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology 236

Mar 02, 2016: Merck Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis 237

Other Significant Developments 238

Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 238

Mar 21, 2017: Merck Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies 239

Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 240

Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 241

Jan 18, 2017: Merck Launches First Commercial Screening Service to Predict Multiple Sources of DNA Damage 243

Nov 15, 2016: Merck Raises Profit Forecast for 2016 Following Good Third Quarter 244

Nov 04, 2016: Merck Invests 250 Million in Production Value Chain in China 246

Sep 21, 2016: Merck Invests over 50 million in Flagship Pharmaceutical Packaging Building in Darmstadt 248

Sep 14, 2016: Merck Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes 249

Jul 19, 2016: MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts 250

Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance 251

May 19, 2016: Merck Increases Sales and Earnings in Q1 Following Sigma-Aldrich Acquisition 252

May 02, 2016: Merck Expands Production Know-how to Deliver Full End-To-End Solution for Biopharma Industry 254

Apr 29, 2016: Merck Annual General Meeting 2016: CEO Handover After Ten Successful Years 255

Feb 24, 2016: Healthcare Supply Chain Academy program launched by International Institute for the Management of Logistics in collaboration with Ferring Pharmaceuticals, Merck and Supply Chain Operations SA 257

Appendix 258

Methodology 258

About GlobalData 258

Contact Us 258

Disclaimer 258

List of Figures

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16

Merck KGaA, Medical Devices Deals, 2011 to YTD 2017 18

List of Tables

Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15

Merck KGaA, Deals By Therapy Area, 2011 to YTD 2017 16

Merck KGaA, Medical Devices Deals, 2011 to YTD 2017 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19

Merck KgaA Acquires SevenSeas Original Brand 29

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 29

SerImmune Raises USD8 Million in Venture Financing 30

TocopheRx Raises USD3.3 Million In Seed Financing 31

VAXIMM Secures USD8 Million In Venture Financing 32

Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 33

Cancer Research Technology Enters into Agreement with Merck 34

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 34

SerImmune Enters into R&D Agreement with Merck 35

Human Longevity Enters into Agreement with Merck 36

F-star Biotech Enters into Partnership with Merck 37

EpiThany Enters into Agreement with Merck and Pfizer 38

VAXIMM Enters into Agreement with Merck and Pfizer 39

Avillion Enters into Co-Development Agreement with Merck 39

Exosome Diagnostics Enters into Agreement with Merck 40

Merck Enters into Agreement with Palantir Technologies 41

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 42

EMD Serono Partners with MD Anderson 43

Evotec Partners with Merck 43

BioMed X Enters into Agreement with Merck 44

Debiopharm Partners with Merck and Pfizer 45

Transgene Enters into Agreement with Merck and Pfizer 46

Vaccinex Enters into Agreement with Merck 47

PCAS Enters into Distribution Agreement with MilliporeSigma 47

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 48

Selvita Enters into Agreement with Merck 49

Merck Enters into Agreement with University of Buea 50

Merck, Pfizer and Verastem Enter into Agreement 50

Merck Enters into Research Agreement with European Molecular Biology Labs 51

Merck, Pfizer and Syndax Pharma Enter into Agreement 52

Selvita Enters into Development and Commercialization Agreement with Merck 53

Biothera Pharma Expands Agreement with Merck 54

Sigma-Aldrich Enters into Agreement with Sanger Institute 54

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 55

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 56

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 56

Aeterna Zentaris Enters into Agreement with EMD Serono 57

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 58

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 59

Merck Serono Enters into Co-Development Agreement with MMV 60

Sigma-Aldrich Enters into Distribution Agreement with Roche 60

Merck Enters into Development Agreement with Precision Biologics 61

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 62

Pfizer Enters into Co-Development Agreement with Merck 62

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 64

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 65

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 65

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 66

Lupin Enters into Co-Development Agreement with Merck Serono 67

Merck Serono Extends R&D Agreement with San Raffaele 68

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 68

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 69

Bionovis Enters into Agreement with Merck 70

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 71

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 72

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 73

Biopharm Enters Into Research Agreement With Merck Serono 73

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 74

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 75

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 76

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 77

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 78

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 79

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 80

Isu Abxis Enters into Co-Development Agreement with Merck 81

Luminex Extends Distribution Agreement With EMD Millipore 82

Alchemia Enters Into Collaboration Agreement with Merck Serono 83

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 83

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 84

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 85

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 85

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 86

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 87

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 88

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 89

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 89

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 90

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 91

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 92

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 93

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 94

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 95

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 95

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 96

Mapi Pharma Amends Co-Development Agreement with Merck 98

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 98

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 99

IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 100

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 101

BASF Enters Into Distribution Agreement With Sigma-Aldrich 102

Lead Discovery Center Enters Into Agreement With Merck Serono 103

Selexis Enters into Licensing Agreement with Merck KGaA 104

Merck Enters into Licensing Agreement with Domain Therapeutics 104

Merck Enters into Licensing Agreement with Vertex Pharma 105

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 106

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 107

Merck Enters into Licensing Agreement with Weizmann Institute of Science 108

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 109

EMD Millipore Enters into Licensing Agreement with Singulex 109

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 110

Intrexon Enters into Licensing Agreement with Merck Serono 111

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 112

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 113

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 114

MorphoSys Enters into Licensing Agreement with Merck Serono 115

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 116

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 117

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 118

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 118

ObsEva Enters Into Licensing Agreement With Merck Serono 119

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 120

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 121

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 123

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 123

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 124

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 125

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 126

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 127

Materia Extends Licensing Agreement With Sigma Aldrich 128

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 129

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 129

Ligand Pharma Enters Into Licencing Agreement With Merck 130

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 131

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 132

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 133

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 134

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 135

WntResearch Enters into Licensing Agreement with EMD Millipore 136

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 137

Sigma Life Science Enters Into Licensing Agreement With King's College London 138

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 138

Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 140

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 141

iOnctura Spin Out from Merck and Cancer Research Technology 142

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 143

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 143

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 144

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 144

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 145

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 146

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 146

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 147

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 148

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 149

Fresenius to Acquire Biosimilars Business from Merck for USD718.4 Million 150

Zydus Healthcare Acquires Six Brands from Merck 151

Martin Dow Acquires Merck Operations in Pakistan 152

Merck May Sell Biosimilars Business 152

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 153

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 154

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 155

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 156

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 157

Merck Sells Bangalore Genei for USD1.5 Million 158

Merck Acquires Sigma-Aldrich for USD17 Billion 158

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 160

Merck And BASF Acquire Majority Stake In Innovation Lab 161

Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For USD39 Million 162

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 164

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 164

Proxy Labs Acquires MicroSafe Laboratories From Millipore 165

Sigma-Aldrich Completes Acquisition Of BioReliance For USD350 Million 166

Sigma-Aldrich Acquires Vetec Quimica Fina 168

Sigma-Aldrich Acquires Resource Technology 168

Teva Pharma Industries Acquires THERAMEX From Merck Serono 169

Merck KGaA, Key Competitors 171

Merck KGaA, Key Employees 172

Merck KGaA, Subsidiaries 173

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merck KGaA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16140
Site License
USD 500 INR 32280
Corporate User License
USD 750 INR 48420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com